Wall Street analysts predict that Allena Pharmaceuticals Inc (NASDAQ:ALNA) will post earnings of ($0.51) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Allena Pharmaceuticals’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.57). Allena Pharmaceuticals reported earnings of ($0.46) per share in the same quarter last year, which would indicate a negative year over year growth rate of 10.9%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 5th.
Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08).
Large investors have recently made changes to their positions in the business. Paloma Partners Management Co purchased a new position in Allena Pharmaceuticals during the second quarter valued at $212,000. Susquehanna International Group LLP bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $137,000. Jane Street Group LLC bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $116,000. Wedbush Securities Inc. bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $63,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Allena Pharmaceuticals by 17.0% during the second quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock valued at $169,000 after purchasing an additional 6,030 shares during the period. Hedge funds and other institutional investors own 65.57% of the company’s stock.
NASDAQ ALNA traded up $0.20 on Thursday, reaching $1.87. The company had a trading volume of 455,644 shares, compared to its average volume of 149,174. The stock has a market capitalization of $39.19 million, a P/E ratio of -1.07 and a beta of 2.02. The company’s fifty day moving average is $4.17 and its 200 day moving average is $4.44. Allena Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $10.66. The company has a quick ratio of 3.96, a current ratio of 3.96 and a debt-to-equity ratio of 0.28.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.